Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
April 17, 2023 09:00 ET
|
Corvus Pharmaceuticals, Inc.
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased...
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
April 03, 2023 08:30 ET
|
Corvus Pharmaceuticals, Inc.
Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023 16:02 ET
|
Corvus Pharmaceuticals, Inc.
New CPI-818 Predictive Biomarker Enables Selection of Lymphoma Patients Most Likely to Benefit from Treatment Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., March 28,...
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
March 21, 2023 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a...
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
March 14, 2023 16:35 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for...
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
February 21, 2023 07:00 ET
|
Corvus Pharmaceuticals, Inc.
Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and...
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
December 12, 2022 10:00 ET
|
Corvus Pharmaceuticals, Inc.
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated...
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
December 05, 2022 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will...
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
November 14, 2022 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
November 03, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and Exposition; Advancing CPI-818 Development for Autoimmune and Allergic Diseases Initiation of a...